

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.

Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: KOSTAKOGLU SHIELDS, LALE

eRA COMMONS USER NAME (credential, e.g., agency login): LKOSTAKOGLU

POSITION TITLE: PROFESSOR OF RADIOLOGY AND MEDICAL IMAGING; DIRECTOR OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
EGE UNIVERSITY FACULTY OF MEDICINE-TURKEY	MD	06/1986	Medicine
COLUMBIA UNIVERSITY, MAILMAN SCHOOL OF PUBLIC HEALTH – NEW YORK	MPH	05/2006	Health Policy

A. Personal Statement

I have had a strong interest in molecular imaging using both qualitative and quantitative methods primarily in oncologic disorders. More specifically, my research has been concentrated in a) development and refining imaging based, mainly PET/CT based, surrogates in evaluating response early during therapy to individualize management b) use of molecular and functional imaging technology to risk-stratify cancer for an effective outcome. My ultimate goal is to help develop management strategies integrating molecular imaging techniques to individualize treatments. I've long been involved in multiple national and international studies using PET-adapted strategies to tailor therapy. I am currently active in developing clinical trials using novel radiopharmaceuticals for imaging and treatment of cancer with the goal of integrating them in treatment algorithms. I'm very excited to join the Hodgkin Lymphoma International STudy for Individual Care (HoLISTIC) consortium to provide my molecular imaging expertise. I'm most enthusiastic to be part of this expert group to model to predict outcome and as a result to develop a decision analytic simulation model integrating molecular imaging findings to project outcomes. I'll also help develop and foster potential future collaborative projects with various objectives integrating qualitative and/or quantitative imaging methods to improve patient care.

I have been involved in numerous NCTN clinical trials in lymphoma and I am currently involved in multiple national and international studies using PET-adapted strategies listed below.

ECOG-ACRIN Imaging co-Chair: E1412, Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma (recruitment completed, open)

ECOG-ACRIN Imaging co-Chair: EA4151, A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

ECOG-ACRIN Imaging co-Chair: E4412, A Phase I/II Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory HL

Alliance Imaging co-Chair. A051301, A randomized phase III study of Ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory DLBCL of the Activated-B-Cell Subtype

SWOG. Imaging substudy co-Chair S1826, A Phase III, Randomized Study OF Nivolumab (Opdivo) Or Brentuximab Vedotin (Adcetris) Plus AVD In Patients (AGE \geq 12 Years) With Newly Diagnosed Advanced Stage Classical HL

B. Positions, Scientific Appointments, and Honors

Positions and Employment

2019 - Current Professor of Radiology, Chief, Nuclear Medicine and Molecular Imaging, Dept Radiology and Medical Imaging, UVA School of Medicine, Charlottesville, VA
2013 - 2019 Professor of Radiology, Chief, Nuclear Medicine and Molecular Imaging-Dept Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York
2006 - 2013 Professor of Radiology, Director, PET/CT Oncology and Research, Dept. Radiology, Icahn School of Medicine at Mount Sinai, New York
2002 - 2006 Associate Professor of Radiology- Dept. Radiology-Div Nuclear Med, New York Presbyterian Hospital Weill Medical College of Cornell University, New York
2000 - 2002 Assistant Professor of Radiology- Dept. Radiology-Div Nuclear Med, New York Presbyterian Hospital Weill Medical College of Cornell University, New York
1998 - 2000 Research Fellow – Dept Radiology, Div Nuclear Med, New York Presbyterian Hospital Weill Medical College of Cornell University, New York
1994 - 1999 Associate Professor –Dept Nuclear Medicine-Hacettepe Univ Faculty of Medicine, Ankara-Turkey

Major Professional Memberships and Scientific Appointments

2018 – present ECOG-ACRIN Immuno-oncology Working Group 1998 – present Society of Nuclear Medicine and Molecular Imaging, (SNMMI)
2016 – present ECOG ACRIN Experimental Imaging Sciences Committee
2014 – present NCI Lymphoma Steering Committee; Imaging and Biomarkers Subcommittee
2011 – present American College of Radiologic Imaging Network (ACRIN), Steering committee
2004 – present Alliance (CALGB), lymphoma subcommittee
2000 – present Radiologic Society of North America (RSNA)

Honors

2012 RSNA Honored Educator Award
2007 Honorary Member, Turkish Society of Hematology and Oncology
2006 Fellow, New York Academy of Medicine
1998 Society of Nuclear Medicine (DuPont Pharma), “Nuclear Oncology” Fellowship award

C. Contribution to Science (selected from 144 publications)

My recent body of work in oncology reflects my strong interest in qualitative and quantitative imaging of cancer using both novel and implemented molecules, in the assessment of extent of disease, response to treatment and also determination of impact on clinical management. I have also been directly involved as a PET imaging expert in the development of currently adopted clinical guidelines in evaluation of response to therapy in lymphoma. These publications overall provided the value of molecular imaging as one of the main components of clinical management agnostic to pathology subtype. Through these publications, it was demonstrated that applying either categorical or quantitative methods to PET imaging in the assessment of disease extent or burden prior to or after treatment has a significant value to individually plan treatment as well as adapt therapies to patients relatively early during the course of treatment. These imaging methodologies and strategies can be agnostic to pathologic conditions both in oncology or neurology and can be extrapolated from one disorder to another by individually fitting the algorithm to the disease in question. My role in any imaging study is to integrate the categorical and quantitative methods to the disease model according to the disease behavior to explore pathways to translate experimental imaging data to clinical applications.

- a. **Kostakoglu L**, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trněný M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. *Blood Adv.* 2021;5:1283-1290.
- b. Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, Wagner-Johnston N, Casulo C, Wade JL, Nagargoje GG, Reynolds CM, Cohen JB, Khan N, Amengual JE, Richards KL, Little RF, Leonard JP, Friedberg JW, **Kostakoglu L**, Kahl BS, Witzig TE. Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. *J Clin Oncol.* 2021;39:1329-1338
- c. **Kostakoglu, L**, Goy, A, Martinelli, G, Caballero, D, Crump, M, Gaidano, G, Baetz, T, Buckstein R, Fine, G, Fingerle-Rowson, G, Berge, C, Sahin, D, Press, O, Sehn, L, FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. *Leuk Lymphoma.* 2016;24:1-10
- d. Barrington SF, Mikhaeel NG, **Kostakoglu L**, Meignan M, Hutchings M, Müller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol.* 2014;32:3048-3058.

Complete List of Published Work in MyBibliography:

<https://www.ncbi.nlm.nih.gov/pubmed/?term=Kostakoglu%2C+L>